Advisors Asset Management Inc. reduced its stake in Natus Medical Incorporated (NASDAQ:BABY) by 56.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,493 shares of the medical equipment provider’s stock after selling 15,146 shares during the period. Advisors Asset Management Inc.’s holdings in Natus Medical were worth $431,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BABY. Louisiana State Employees Retirement System increased its holdings in shares of Natus Medical by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 13,500 shares of the medical equipment provider’s stock valued at $504,000 after purchasing an additional 100 shares during the last quarter. Aperio Group LLC increased its holdings in shares of Natus Medical by 7.0% in the second quarter. Aperio Group LLC now owns 6,583 shares of the medical equipment provider’s stock valued at $246,000 after purchasing an additional 429 shares during the last quarter. Strs Ohio increased its holdings in shares of Natus Medical by 1,106.9% in the second quarter. Strs Ohio now owns 105,000 shares of the medical equipment provider’s stock valued at $3,916,000 after purchasing an additional 96,300 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its holdings in shares of Natus Medical by 3.2% in the second quarter. Municipal Employees Retirement System of Michigan now owns 7,760 shares of the medical equipment provider’s stock valued at $289,000 after purchasing an additional 240 shares during the last quarter. Finally, Great West Life Assurance Co. Can increased its holdings in shares of Natus Medical by 3.0% in the second quarter. Great West Life Assurance Co. Can now owns 48,240 shares of the medical equipment provider’s stock valued at $1,796,000 after purchasing an additional 1,383 shares during the last quarter. Hedge funds and other institutional investors own 94.39% of the company’s stock.

Several research firms recently commented on BABY. Zacks Investment Research upgraded shares of Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a research note on Tuesday, October 24th. BidaskClub downgraded shares of Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Natus Medical currently has a consensus rating of “Hold” and an average price target of $46.50.

Natus Medical Incorporated (NASDAQ:BABY) opened at $38.80 on Wednesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36. Natus Medical Incorporated has a one year low of $31.65 and a one year high of $43.60. The company has a market cap of $1,227.47, a PE ratio of 25.42 and a beta of 0.84.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.02. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The business had revenue of $122.60 million for the quarter, compared to the consensus estimate of $122.41 million. During the same period in the prior year, the company posted $0.39 earnings per share. Natus Medical’s revenue was up 34.9% compared to the same quarter last year. research analysts anticipate that Natus Medical Incorporated will post 1.74 EPS for the current fiscal year.

In other Natus Medical news, Director Robert A. Gunst sold 4,400 shares of the stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $35.17, for a total transaction of $154,748.00. Following the sale, the director now directly owns 50,850 shares in the company, valued at $1,788,394.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director William M. Moore sold 5,000 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The disclosure for this sale can be found here. Insiders have sold 22,042 shares of company stock worth $902,266 over the last quarter. Corporate insiders own 5.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://theolympiareport.com/2017/12/06/advisors-asset-management-inc-decreases-holdings-in-natus-medical-incorporated-baby.html.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.